Clinical Trial News and Research

RSS

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Seattle Genetics, Inc. today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA.

28 Jan 2013

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

27 Jan 2013

Mount Sinai sets up new center for treating tic and obsessive-compulsive disorders

Mount Sinai has officially opened a new center to treat and research tic and obsessive-compulsive disorders (OCD) in individuals of all ages. The opening coincides with a significant revision in the psychiatry field's manual of mental disorders, which will now recognize OCD with its own category, rather than classifying it as an anxiety disorder.

25 Jan 2013

New hope for lupus patients

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.

25 Jan 2013

Researchers initiate first gene therapy clinical trial for Fabry disease

Researchers in Calgary have launched the first gene therapy clinical trial in the world for Fabry disease, a rare inherited enzyme deficiency that can shorten the lifespan of people who have it by as much as 40 years.

24 Jan 2013

Gastrointestinal Cancers Symposium to be held from Jan. 24-26 in San Francisco, CA

New research into the treatment and prognosis of gastrointestinal cancers was released today in advance of the tenth annual Gastrointestinal Cancers Symposium being held January 24-26, 2013, at The Moscone West Building in San Francisco, CA.

24 Jan 2013

Clinical trial to evaluate cyclodextrin against Niemann-Pick disease type C1

A clinical trial to evaluate a drug candidate called cyclodextrin as a possible treatment for Niemann-Pick disease type C1 (NPC), a rare and fatal genetic disease, will start today, researchers announced.

24 Jan 2013

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).

24 Jan 2013

Positive results from BioInvent's BI-505 phase I study on multiple myeloma

BioInvent International announced today the first results from the BI-505 phase I study in patients with multiple myeloma.

24 Jan 2013

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide.

24 Jan 2013

NIH's candidate vaccine safe in treating dengue

A candidate dengue vaccine developed by scientists at the National Institutes of Health (NIH) has been found to be safe and to stimulate a strong immune response in most vaccine recipients, according to results from an early-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. The trial results were published online on January 17 in the Journal of Infectious Diseases.

23 Jan 2013

Interventional Radiology launches IR Quarterly magazine

Interventional Radiology announces the launch of IR Quarterly-a new magazine that communicates updates critical to the practice of interventional radiology, augmented with stories, interviews and in-depth analysis in each four-color, 40-page issue. IR Quarterly delivers quality reporting on political advocacy, practice management and the latest specialty news and information.

23 Jan 2013

Gene therapy does not slow or halt progression of cell loss in Leber congenital amaurosis

Independent clinical trials, including one conducted at the Scheie Eye Institute at the Perelman School of Medicine, have reported safety and efficacy for Leber congenital amaurosis (LCA), a congenital form of blindness caused by mutations in a gene (RPE65) required for recycling vitamin A in the retina. Inherited retinal degenerative diseases were previously considered untreatable and incurable.

23 Jan 2013

SLU team discovers molecular pathway that contributes to triple-negative breast cancer

In research published in the Jan. 17 issue of The Journal of Cell Biology, a team led by Susana Gonzalo, Ph.D., assistant professor of biochemistry and molecular biology at Saint Louis University, has discovered a molecular pathway that contributes to triple-negative breast cancer, an often deadly and treatment resistant form of cancer that tends to strike younger women.

23 Jan 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

CHLA, House Research Institute receive FDA approval to begin pediatric ABI clinical trial

L.A.-based House Research Institute and Children's Hospital Los Angeles announced today that the United States Food and Drug Administration (FDA) has given final approval to begin a clinical trial of an Auditory Brainstem Implant (ABI) procedure for children.

22 Jan 2013

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.

22 Jan 2013

Gene therapy improves vision but does not halt progression of cell loss

22 Jan 2013

Scientists figure out how to dodge HPV-triggered cancers by vaccination

In 2009, more than 30,000 people in the U.S. learned they had cancer linked to the human papillomavirus, or HPV. This virus is best known for causing cervical cancer, but it's also the culprit behind many cancers of the mouth, throat, anus, and genitals. Unlike many forms of cancer, for which we lack the knowledge and tools to prevent, scientists have figured out how to dodge HPV-triggered cancers — by HPV vaccination.

19 Jan 2013

CRF to sponsor 8th International Conference on Cell Therapy for Cardiovascular Disease

The final agenda for the Eighth International Conference on Cell Therapy for Cardiovascular Disease, sponsored by the Cardiovascular Research Foundation, is now available online.

19 Jan 2013

Clinical Trial News and Research

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

Mount Sinai sets up new center for treating tic and obsessive-compulsive disorders

New hope for lupus patients

Researchers initiate first gene therapy clinical trial for Fabry disease

Gastrointestinal Cancers Symposium to be held from Jan. 24-26 in San Francisco, CA

Clinical trial to evaluate cyclodextrin against Niemann-Pick disease type C1

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

Positive results from BioInvent's BI-505 phase I study on multiple myeloma

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

NIH's candidate vaccine safe in treating dengue

Interventional Radiology launches IR Quarterly magazine

Gene therapy does not slow or halt progression of cell loss in Leber congenital amaurosis

SLU team discovers molecular pathway that contributes to triple-negative breast cancer

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

CHLA, House Research Institute receive FDA approval to begin pediatric ABI clinical trial

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Gene therapy improves vision but does not halt progression of cell loss

Scientists figure out how to dodge HPV-triggered cancers by vaccination

CRF to sponsor 8th International Conference on Cell Therapy for Cardiovascular Disease

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer